Ionis Pharmaceuticals, Inc.
IONS
$75.83
$0.450.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 246.09M | 203.33M | 156.72M | 452.05M | 131.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 246.09M | 203.33M | 156.72M | 452.05M | 131.61M |
| Cost of Revenue | 213.16M | 287.60M | 220.09M | 221.61M | 202.22M |
| Gross Profit | 32.94M | -84.27M | -63.37M | 230.44M | -70.61M |
| SG&A Expenses | 150.36M | 130.19M | 96.81M | 90.62M | 76.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 363.52M | 417.79M | 316.90M | 312.23M | 278.47M |
| Operating Income | -117.42M | -214.46M | -160.18M | 139.82M | -146.86M |
| Income Before Tax | -92.31M | -227.92M | -128.39M | 123.53M | -146.82M |
| Income Tax Expenses | 218.00K | 1.48M | 213.00K | -20.00K | 116.00K |
| Earnings from Continuing Operations | -92.53M | -229.39M | -128.61M | 123.55M | -146.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -92.53M | -229.39M | -128.61M | 123.55M | -146.94M |
| EBIT | -117.42M | -214.46M | -160.18M | 139.82M | -146.86M |
| EBITDA | -113.46M | -210.56M | -157.31M | 142.68M | -144.05M |
| EPS Basic | -0.56 | -1.42 | -0.81 | 0.78 | -0.93 |
| Normalized Basic EPS | -0.44 | -0.82 | -0.62 | 0.56 | -0.57 |
| EPS Diluted | -0.56 | -1.42 | -0.81 | 0.70 | -0.93 |
| Normalized Diluted EPS | -0.44 | -0.82 | -0.62 | 0.49 | -0.57 |
| Average Basic Shares Outstanding | 164.87M | 162.00M | 159.77M | 159.14M | 158.74M |
| Average Diluted Shares Outstanding | 164.87M | 162.00M | 159.77M | 182.33M | 158.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |